Stockscreener 앱 받기
1.42
1.39%
-0.02
시장 영업 전:
1.30
-0.12
-8.45%
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics (ADCT) Expected to Announce Earnings on Monday - MarketBeat
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday - Defense World
LPL Financial LLC Invests $50,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
BlackRock, Inc. Reduces Stake in ADC Therapeutics SA - GuruFocus
Geode Capital Management LLC Acquires 9,938 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data a - GuruFocus
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 - BioSpace
Stock Market Recap: Adc Therapeutics SA (ADCT) Concludes at 1.41, a -5.37 Surge/Decline - DWinneX
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data at AACR 2025 | ADCT Stock News - GuruFocus
Breakthrough Cancer Drug Shows 100% Tumor Response in Ovarian, Lung Cancer Models: AACR 2025 Data Reveals - Stock Titan
Russell Investments Group Ltd. Buys 9,248 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Seeking Alpha
Antibody Drug Conjugate Market to Witness Upsurge in Growth - openPR.com
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting - marketscreener.com
Sei Investments Co. Invests $46,000 in ADC Therapeutics SA (NYSE:ADCT) - The AM Reporter
Sei Investments Co. Makes New $46,000 Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Prudential Financial Inc. Invests $35,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Neuroendocrine tumors Pipeline Analysis and Clinical Trials - openPR.com
SEC Form PRE 14A filed by ADC Therapeutics SA - Quantisnow
HC Wainwright Lifts Earnings Estimates for ADC Therapeutics - MarketBeat
ADC Therapeutics : 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
Analyzing Ratios: Adc Therapeutics SA (ADCT)’s Financial Story Unveiled - DWinneX
ADC Therapeutics SA (NYSE:ADCT) Sees Large Decline in Short Interest - MarketBeat
Research Analysts Set Expectations for ADCT Q1 Earnings - Defense World
Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight - The Globe and Mail
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
NBE Therapeutics opens ADC research facility in Switzerland - Pharmaceutical Technology
ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
ADC Therapeutics (NYSE:ADCT) Given New $7.00 Price Target at Guggenheim - MarketBeat
ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Bradford Era
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - Defense World
ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating By Investing.com - Investing.com UK
Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating - Investing.com
Bank of New York Mellon Corp Buys 9,750 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ADC Therapeutics Q4 2024 beats EPS, misses revenue - Investing.com Australia
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
0.39%
3.66%
자본화:
|
볼륨(24시간):